CellGENTherapies
CellGENTherapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).
We focus on the development and production of small batches of ATMPs (including personalized products) and prophylactic RNA vaccines for phase I studies helping UZ Gent, external clients and partners to move their research “from bench to bedside”.
News & Events
-
We’re hiring: Head of CellGENTherapies
Ghent University Hospital is seeking a Head of CellGENTherapies. CellGENTherapies is at the core of the development and production of advanced gene therapy, cell therapy, and tissue-based products, as well as prophylactic RNA vaccines for early-phase (Phase I) clinical studies. The focus is on small-batch production, including personalized therapeutics, within a strongly translational environment. CellGENTherapies…
-
CellGENTherapies part of the THEODORA project: the fight against pediatric cancer Ewing sarcoma
This September month, Institut Curie, the Princess Máxima Center for pediatric oncology and Hopp Children’s Cancer Center Heidelberg (KiTZ) announce the launch of the European THEODORA project to accelerate the development and clinical evaluation of new immunotherapies against Ewing sarcoma, an aggressive cancer that mainly affects adolescents and young adults. Funded with €13.2 million by…
CellGENTherapies is a member of
Vaxadvance is an initiative at Ghent University Hospital driven by four high level expertise centra who have strengthen their forces with the goal to accelerate breakthroughs in vaccine and therapeutic development.
- NanoMedicine Centre: nanoparticle-based formulation services
- the GMP unit CellGENTherapies: GMP production of ATMPs for early phase clinical trials
- the core ARTH Animal Facilities: lab animal-based preclinical research
- the Center for Vaccinology CEVAC: dedicated trial center Phase I – IV and Immuno-monitoring
With Vaxadvance, Ghent University Hospital continues playing a crucial role in driving the future of vaccine innovation.
Partners
Sponsors
